Bio-UV Group SA (ALTUV) AI Stock Analysis

• Market Cap: €22.29M
• Dividend Yield: 3.26%
• Average Volume (3M): 11.57K
• Price to Earnings (P/E): 25.5
• Beta (1Y): 0.54
• Revenue Growth: -7.99%
• EPS Growth: N/A
• Country: FR
• Employees: 155
• Sector: Industrials
• Sector Strength: 72
• Industry: Waste Management
• EPS (TTM): 0.10
• Shares Outstanding: 14,154,679
• 10 Day Avg. Volume: 18,064
• 30 Day Avg. Volume: 11,570
• PEG Ratio: -9.61
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.58
• P/FCF Ratio: 4.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €1.50
• Price Target Upside: -7.98% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: €1.50 ▼(-7.98% Downside)

The overall stock score of 48 reflects significant challenges in financial performance, with declining revenue and profitability. Technical analysis indicates bearish momentum, further weighing on the stock's outlook. While the valuation is moderate, the lack of dividend yield reduces its appeal. The absence of earnings call insights and corporate events leaves the focus on existing financial and technical data.

Bio-UV Group SA Business Overview & Revenue Model

Company Description

Bio-UV Group SA (ALTUV) specializes in the design and manufacturing of advanced disinfection systems utilizing ultraviolet (UV) technology. Operating primarily in the water treatment and sanitation sectors, the company offers a range of products that cater to various applications, including swimming pools, aquaculture, drinking water, and industrial processes. Bio-UV Group is committed to providing eco-friendly solutions that enhance water quality while minimizing environmental impact.

How the Company Makes Money

Bio-UV Group generates revenue through the sale of its UV disinfection systems and related equipment. The company has multiple key revenue streams, including direct sales of UV systems to end-users in various industries, ongoing maintenance and service contracts, and the provision of replacement parts for its equipment. Additionally, Bio-UV Group may benefit from strategic partnerships with distributors and industry players that expand its market reach and enhance product visibility. The company also engages in research and development to innovate and improve its product offerings, which can lead to new revenue opportunities in emerging markets.

Bio-UV Group SA Financial Statement Overview

Summary

Bio-UV Group SA faces challenges in revenue growth and profitability, with declining sales and low net margins. While leverage has improved, the company struggles to generate strong returns on equity. Cash flow management shows inconsistencies, highlighting the need for better operational efficiency and strategic financial planning to enhance stability and growth.

Income Statement

The income statement shows a declining revenue trend with a negative growth rate in the latest year, indicating potential challenges in sales. Gross profit margins have improved over the years, but net profit margins remain very low, suggesting limited profitability. The EBIT and EBITDA margins are modest, reflecting operational efficiency but also highlighting the need for cost control and revenue growth.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio, which has improved recently, indicating better leverage management. However, the return on equity is minimal, suggesting that the company is not generating significant returns on shareholder investments. The equity ratio is stable, reflecting a balanced asset structure.

Cash Flow

Cash flow analysis indicates fluctuating free cash flow growth, with recent declines. The operating cash flow to net income ratio is low, suggesting challenges in converting income into cash. The free cash flow to net income ratio is relatively healthy, but overall cash flow management needs improvement to support operations and growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	38.21M	39.58M	43.13M	51.29M	33.46M	32.17M
Gross Profit	12.61M	24.09M	25.58M	4.71M	1.84M	1.78M
EBITDA	-17.51M	4.18M	4.43M	6.38M	3.35M	1.71M
Net Income	965.41K	31.36K	124.89K	2.42M	689.38K	583.95K
Balance Sheet
Total Assets	73.39M	66.09M	71.41M	74.08M	81.12M	51.92M
Cash, Cash Equivalents and Short-Term Investments	9.36M	3.87M	2.73M	1.98M	10.57M	12.57M
Total Debt	21.11M	23.99M	28.27M	29.15M	30.74M	13.66M
Total Liabilities	32.00M	33.40M	39.19M	41.74M	50.43M	21.72M
Stockholders Equity	41.32M	32.69M	32.22M	32.24M	30.52M	30.20M
Cash Flow
Free Cash Flow	2.27M	5.00M	4.28M	476.03K	571.69K	-3.32M
Operating Cash Flow	4.77M	6.90M	6.24M	2.70M	3.30M	-121.86K
Investing Cash Flow	-1.95M	-1.87M	-1.95M	-8.95M	-20.70M	-3.20M
Financing Cash Flow	3.11M	-3.73M	-3.57M	-2.50M	15.53M	14.35M

Bio-UV Group SA Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.63
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALTUV, the sentiment is Neutral. The current price of 1.63 is below the 20-day moving average (MA) of 1.65, below the 50-day MA of 1.70, and below the 200-day MA of 1.90, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 54.74 is Neutral, neither overbought nor oversold. The STOCH value of 56.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:ALTUV.

Bio-UV Group SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AURE	54 Neutral	€50.64M	-31.53	1.44%	―	-11.23%	43.27%
ALTUV	48 Neutral	€22.29M	25.45	―	3.26%	-7.99%	―
OREGE	40 Underperform	€15.05M	-1.24	17.12%	―	103.54%	-19.23%
ALEUP	37 Underperform	€2.25M	-0.66	146.90%	―	175.55%	100.00%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%